Woodline Partners »

Immunic shares owned by Woodline Partners

Quarter-by-quarter ownership of Immunic (IMUX) shares owned by Woodline Partners from 13F filings

Historical chart of Woodline Partners investment in Immunic

Tip: Access up to 7 years of quarterly data

All positions including Immunic held by Woodline Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Immunic by Woodline Partners

Quarter filed Position value Share count Share price at filing
2024-09-30 $196k 119k 1.65

More positions owned by Woodline Partners

Meta Platforms Cl A (META)
Gilead Sciences (GILD)
Abbvie (ABBV)
Revolution Medicines (RVMD)
Vaxcyte (PCVX)
Asml Holding N V N Y Registry Shs (ASML)
Nuvalent Inc-a (NUVL)
Permian Resources Corp Class A Com (PR)
Encana Corporation (OVV)
Keysight Technologies (KEYS)
Danaher Corporation (DHR)
Aon Shs Cl A (AON)
Stmicroelectronics N V Ny Registry (STM)
Regeneron Pharmaceuticals (REGN)
EQT Corporation (EQT)

View all positions for Woodline Partners

Top funds holding Immunic

BVF
Avidity Partners Management
Colony
Geode Capital Management
Susquehanna International
BlackRock
683 Capital Management
Ikarian Capital
Marshall Wace
Renaissance Technologies
Citadel Advisors
Northern Trust
Woodline Partners
Citigroup
Connor, Clark & Lunn Investment Management

View all funds holding Immunic